Spencer Pharmaceutical said the patents are related to platform technologies for the efficient delivery of nucleic acids using chitosan as well as for an innovative discovery of therapeutic nanocomplexes for type 2 diabetes treatment in addition to other possible derivative applications.
Spencer Pharmaceutical CEO Arella said they are proud of having concluded this negotiation with Polyvalor and the Spencer team are looking forward to amalgamating the drug-discovery/delivery research of Buschmann’s group with the ongoing pipeline of drug-delivery systems development by Spencer that are already undergoing animal studies in their company.